Large owner Walgreens Boots Alliance, Inc. sold $314,531,796 worth of shares (1,286,376 units at $244.51) (SEC Form 4)

2/10/25 7:35:38 PM ET

$WBA

Retail-Drug Stores and Proprietary Stores

Consumer Staples

Get the next $WBA alert in real time by email

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walgreens Boots Alliance, Inc.

(Last)

(First)

(Middle)

108 WILMOT ROAD

(Street)

DEERFIELD

60015

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Cencora, Inc. [ COR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/06/2025		S⁽¹⁾		1,081,885	D	$244.51	18,898,115⁽⁸⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Common Stock	02/06/2025		J/K⁽²⁾⁽³⁾⁽⁵⁾		2,159,136	D	$244.51	16,738,979⁽⁸⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Common Stock	02/06/2025		J/K⁽²⁾⁽³⁾⁽⁵⁾		1,323,172	D	$244.51	15,415,807⁽⁸⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Common Stock	02/06/2025		J/K⁽²⁾⁽³⁾⁽⁵⁾		436,653	D	$244.51	14,979,154⁽⁸⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Common Stock	02/06/2025		J/K⁽²⁾⁽³⁾⁽⁵⁾		437,884	D	$244.51	14,541,270⁽⁸⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Common Stock	02/06/2025		J/K⁽²⁾⁽⁴⁾⁽⁶⁾		879,015	D	$244.51	13,662,255⁽⁸⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Common Stock	02/06/2025		J/K⁽²⁾⁽⁴⁾⁽⁶⁾		439,989	D	$244.51	13,222,266⁽⁸⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Common Stock	02/06/2025		J/K⁽²⁾⁽⁴⁾⁽⁶⁾		447,775	D	$244.51	12,774,491⁽⁸⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Common Stock	02/06/2025		S⁽⁷⁾		204,491	D	$244.51	12,570,000⁽⁸⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Forward sale contract (obligation to sell)	⁽²⁾⁽³⁾⁽⁵⁾	02/06/2025		J/K⁽²⁾⁽³⁾⁽⁵⁾			2,625,000	⁽²⁾⁽³⁾⁽⁵⁾	⁽²⁾⁽³⁾⁽⁵⁾	Common Stock	2,625,000	$0⁽²⁾⁽³⁾⁽⁵⁾	0⁽²⁾⁽³⁾⁽⁵⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Forward sale contract (obligation to sell)	⁽²⁾⁽³⁾⁽⁵⁾	02/06/2025		J/K⁽²⁾⁽³⁾⁽⁵⁾			1,575,000	⁽²⁾⁽³⁾⁽⁵⁾	⁽²⁾⁽³⁾⁽⁵⁾	Common Stock	1,575,000	$0⁽²⁾⁽³⁾⁽⁵⁾	0⁽²⁾⁽³⁾⁽⁵⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Forward sale contract (obligation to sell)	⁽²⁾⁽³⁾⁽⁵⁾	02/06/2025		J/K⁽²⁾⁽³⁾⁽⁵⁾			525,000	⁽²⁾⁽³⁾⁽⁵⁾	⁽²⁾⁽³⁾⁽⁵⁾	Common Stock	525,000	$0⁽²⁾⁽³⁾⁽⁵⁾	0⁽²⁾⁽³⁾⁽⁵⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Forward sale contract (obligation to sell)	⁽²⁾⁽³⁾⁽⁵⁾	02/06/2025		J/K⁽²⁾⁽³⁾⁽⁵⁾			525,000	⁽²⁾⁽³⁾⁽⁵⁾	⁽²⁾⁽³⁾⁽⁵⁾	Common Stock	525,000	$0⁽²⁾⁽³⁾⁽⁵⁾	0⁽²⁾⁽³⁾⁽⁵⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Forward sale contract (obligation to sell)	⁽²⁾⁽⁴⁾⁽⁶⁾	02/06/2025		J/K⁽²⁾⁽⁴⁾⁽⁶⁾			1,080,000	⁽²⁾⁽⁴⁾⁽⁶⁾	⁽²⁾⁽⁴⁾⁽⁶⁾	Common Stock	1,080,000	$0⁽²⁾⁽⁴⁾⁽⁶⁾	0⁽²⁾⁽⁴⁾⁽⁶⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Forward sale contract (obligation to sell)	⁽²⁾⁽⁴⁾⁽⁶⁾	02/06/2025		J/K⁽²⁾⁽⁴⁾⁽⁶⁾			540,000	⁽²⁾⁽⁴⁾⁽⁶⁾	⁽²⁾⁽⁴⁾⁽⁶⁾	Common Stock	540,000	$0⁽²⁾⁽⁴⁾⁽⁶⁾	0⁽²⁾⁽⁴⁾⁽⁶⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾
Forward sale contract (obligation to sell)	⁽²⁾⁽⁴⁾⁽⁶⁾	02/06/2025		J/K⁽²⁾⁽⁴⁾⁽⁶⁾			540,000	⁽²⁾⁽⁴⁾⁽⁶⁾	⁽²⁾⁽⁴⁾⁽⁶⁾	Common Stock	540,000	$0⁽²⁾⁽⁴⁾⁽⁶⁾	0⁽²⁾⁽⁴⁾⁽⁶⁾	I	See footnotes⁽⁸⁾⁽⁹⁾⁽¹⁰⁾

1. Name and Address of Reporting Person^*

Walgreens Boots Alliance, Inc.

(Last)

(First)

(Middle)

108 WILMOT ROAD

(Street)

DEERFIELD

60015

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Walgreens Boots Alliance Holdings LLC

(Last)

(First)

(Middle)

C/O 108 WILMOT ROAD

(Street)

DEERFIELD

60015

(City)

(State)

(Zip)

Relationship of Reporting Person(s) to Issuer

Director	X	10% Owner
Officer (give title below)		Other (specify below)

Explanation of Responses:

1. Represents a block sale pursuant to Rule 144 under the Securities Act of 1933, as amended, to an unaffiliated financial institution by Walgreens Boots Alliance Holdings LLC (the "Block Sale").

2. On February 6, 2025, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into early settlement agreements (the "Settlement Agreements") with a number of unaffiliated financial institutions to early settle existing variable pre-paid forward sale contracts (the "Contracts").

3. The Contracts were entered into by Counterparty and the unaffiliated financial institutions on August 3,2023. As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 5,250,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. Counterparty also pledged 5,250,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $797.2 million on or about the date of entering into the Contracts.

4. The Contracts were entered into by Counterparty and the unaffiliated financial institutions on November 9, 2023. As previously disclosed, the Contracts obligated Counterparty to deliver to the financial institutions in the aggregate up to 2,160,000 shares of Common Stock (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and could entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. Counterparty also pledged 2,160,000 shares of Common Stock in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $339.1 million on or about the date of entering into the Contracts.

5. While the Contracts were scheduled to mature evenly over a series of 30 valuation dates from March 2, 2026 to April 13, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$9,542,637.31.

6. While the Contracts were scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive, pursuant to the terms of the relevant Settlement Agreements, Counterparty and each such financial institution agreed to settle the Contracts prior to their scheduled maturity date based on a price per share of Common Stock equal to the price of the Block Sale disclosed herein, Counterparty has agreed to deliver to each of the financial institutions the in settlement of the Contracts the number of shares of Common Stock indicated in Table I above, and Counterparty has agreed to pay to the financial institutions cash in a net aggregate amount equal to US$10,433,585.66.

7. Represents a sale in a private transaction to the Issuer by Walgreens Boots Alliance Holdings LLC.

8. As previously disclosed, including in the Schedule 13D filed by Walgreen Co. ("Walgreens") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023, November 14, 2023, February 9, 2024, August 5, 2024 and August 20, 2024 (the "Walgreens Schedule 13D"), the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer.

9. The Contracts were held by Counterparty and the Settlement Agreements were entered into by Counterparty.

10. As described in the Walgreens Schedule 13D, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4.

	/s/ Joseph B. Amsbary, Senior Vice President and Corporate Secretary of Reporting Person	02/10/2025
	/s/ Joseph B. Amsbary, Vice President and Secretary of Counterparty	02/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Get the next $WBA alert in real time by email

Date	Price Target	Rating	Analyst
2/28/2025	$11.00 → $9.00	Hold → Sell	Deutsche Bank
2/26/2024	$23.00	Market Perform	Leerink Partners
2/20/2024		Hold → Reduce	HSBC Securities
1/3/2024	$21.00	Underweight	Barclays
12/22/2023	$27.00	Hold	HSBC Securities
10/23/2023	$27.00 → $30.00	Neutral → Overweight	JP Morgan
7/3/2023	$37.00 → $27.00	Underweight	Morgan Stanley
6/28/2023	$46.00 → $34.00	Buy → Hold	Deutsche Bank

Large owner Walgreens Boots Alliance, Inc. sold $314,531,796 worth of shares (1,286,376 units at $244.51) (SEC Form 4)

Chat with this insight

Recent Analyst Ratings for $WBA

$WBA Leadership Updates

Live Leadership Updates

Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

Walgreens Appoints Two New Leaders to its Retail and Customer Experience Team

Super Micro Computer Inc. to Join the Nasdaq-100 Index® Beginning July 22, 2024

$WBA Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc. (Amendment)

$WBA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Walgreens Boots Alliance downgraded by Deutsche Bank with a new price target

Leerink Partners initiated coverage on Walgreens Boots Alliance with a new price target

Walgreens Boots Alliance downgraded by HSBC Securities

$WBA SEC Filings

SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

Amendment: SEC Form SCHEDULE 13D/A filed by Walgreens Boots Alliance Inc.

$WBA FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

$WBA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

Mahajan Manmohan bought $116,280 worth of shares (6,000 units at $19.38) (SEC Form 4)

$WBA Press Releases

Fastest customizable press release news feed in the world

Walgreens Committed to Supporting Rite Aid Customers and Employees

Walgreens Debuts PharmStart to Strengthen the Tech to Pharmacist Pipeline

Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday, April 26, 2025

$WBA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

SEC Form 4 filed by Director Lederer John Anthony

SEC Form 4 filed by Director Huffines Robert Luther

$WBA Financials

Live finance-specific insights

Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results

Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

Walgreens Boots Alliance Suspends Quarterly Dividend as Company Continues Disciplined Execution Against Strategic Priorities

Recent Analyst Ratings for
$WBA

$WBA
Leadership Updates

$WBA
Large Ownership Changes

$WBA
Analyst Ratings

$WBA
SEC Filings

$WBA
FDA approvals

$WBA
Insider Purchases

$WBA
Press Releases

$WBA
Insider Trading

$WBA
Financials